Cyclamic Acid

Cyclamic Acid

SCHEMBL120573

O=S(=O)(O)NC1CCCCC1.[NaH]

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.61
CA7 P43166 3/20 0.61
CA14 Q9ULX7 3/20 0.61
CA1 P00915 2/20 0.61
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 2/20 0.45
RECQL P46063 1/20 0.45
EPHX1 P07099 5/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP3A4 P08684 2/20 0.42
MAPT P10636 1/20 0.42
EPHX2 P34913 1/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclamic Acid SCHEMBL11003910 1.00 CA12 (0.61) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL10999470 1.00 CA12 (0.61) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL29287057 0.98 CA12 (0.58) CA12CA7CA14CA1CA2
SCHEMBL1726858 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
SCHEMBL1726879 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL11686696 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL6227 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
SCHEMBL1727205 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
SCHEMBL1727915 0.97 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL18585752 0.97 CA12 (0.64) CA12CA7CA14CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250082623-A1 COMPOSITIONS CONTAINING FEXOFENADINE OPELLA HEALTHCARE GROUP SAS (FR) 2025-03-13 US claimed
WO-2024264012-A1 BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS INCLUDING ANTHELMINITIC BENZIMIDAZOLE COMPOUNDS AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-12-26 WO claimed
WO-2024264013-A1 BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-12-26 WO claimed
CN-117923831-B Retarding water reducer 山东同盛建材有限公司 2024-05-28 CN claimed
CN-117923831-A Retarding water reducer 山东同盛建材有限公司 2024-04-26 CN claimed
WO-2023126637-A1 COMPOSITIONS CONTAINING FEXOFENADINE OPELLA HEALTHCARE GROUP SAS (FR) 2023-07-06 WO claimed
CN-110279636-A A kind of whitening promoting and tooth-building toothpaste and preparation method thereof 张衡 2019-09-27 CN claimed
CN-110123660-A Peptides oral health toothpaste containing victory and preparation method thereof 上海利盛生特企业发展有限公司 2019-08-16 CN claimed
CN-109715170-A The composition and method for preventing or treating fatty pancreas, improve pancreopathy change caused by fatty pancreas, diabetes or other associated diseases 财团法人国际教育基金会 2019-05-03 CN claimed
CN-109674719-A Herbal mixture Caulis Spatholobi toothpaste and preparation method thereof 夏祥华 2019-04-26 CN claimed
CN-1931138-A Entecavir granule and its prepn process HENAN FUREN PHARMACEUTICAL IND (CN) 2007-03-21 CN claimed
CN-1302774-C Efferverscent tablets containing troxerutin and their preparation QIU XUELIANG (CN) 2007-03-07 CN claimed
CN-1613444-A Efferverscent tablets containing troxerutin and their preparation QIU XUELIANG (CN) 2005-05-11 CN claimed
CN-1476300-A Calcium-added beverage and production method thereof ���¿��ֹ�˾ 2004-02-18 CN claimed
WO-2003082251-A2 THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 α METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION HEMOFARM KONCERN A.D. PHARMACEUTICAL AND CHEMICAL INDUSTRY (YU) 2003-10-09 WO claimed
CN-1421206-A Medical composition GLAXO GROUP LTD (GB) 2003-06-04 CN claimed
CN-1351488-A Drinkable pharmaceutical suspensions ETHYPHARM LAB PROD ETHIQUES (FR) 2002-05-29 CN claimed
US-6083549-A IMPROVING TASTE OF SWEETENERS OR FOODS AJINOMOTO CO., INC. (JP) 2000-07-04 US claimed
US-5500668-A INK JET PRINTING XEROX CORPORATION (US) 1996-03-19 US claimed
US-4680064-A Phosphate conversion coating accelerators GERHARD COLLARDIN GMBH (DE) 1987-07-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250082623-A1 COMPOSITIONS CONTAINING FEXOFENADINE HRH2, IL5, HRH1 CA12 94/4885CA7 520/4885CA14 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.